Sugi Predict

Sugi Predict / Compounds / SCHEMBL20120628

SCHEMBL20120628

SCHEMBL20120628

Cc1ccc(S(=O)(=O)OCCCC(F)(F)COC2CCCCO2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SLC12A2 P55011 1/20 0.35
▸ SLC12A5 Q9H2X9 1/20 0.35
▸ CASP3 P42574 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ TSHR P16473 2/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GAA P10253 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ ENPP3 O14638 2/20 0.32
▸ ENPP1 P22413 2/20 0.32
▸ ENPP2 Q13822 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11016658 0.86 MEN1 (0.47) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL11014343 0.85 MEN1 (0.49) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL10972726 0.85 MEN1 (0.49) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL22070845 0.83 MEN1 (0.45) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL20120351 0.83 MEN1 (0.45) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL1934479 0.83 MEN1 (0.43) MEN1KMT2ASLC12A2SLC12A5ALDH1A1
SCHEMBL8761796 0.82 CASP3 (0.35) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL20305757 0.81 MEN1 (0.46) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL22071053 0.81 MEN1 (0.45) MEN1KMT2ASLC12A2SLC12A5CASP3
SCHEMBL31683471 0.80 MEN1 (0.44) MEN1KMT2ASLC12A2SLC12A5CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 — — US disclosed
CN-119954801-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-05-09 — — CN disclosed
CN-114867727-B TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-02-21 — — CN disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-23 — — US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 — — US disclosed
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-10-04 — — US disclosed
CN-114867727-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-08-05 — — CN disclosed
EP-3999182-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2022-05-25 — — EP disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 — — WO disclosed
EP-3535265-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2019-09-11 — — EP disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT MEN1 1910/4885KMT2A 1588/4885SLC12A2 3632/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MEN1 1944/4885KMT2A 1250/4885SLC12A2 3690/4885
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885SLC12A2 3778/4885
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885SLC12A2 3778/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885SLC12A2 3778/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT MEN1 1910/4885KMT2A 1588/4885SLC12A2 3632/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN MEN1 1955/4885KMT2A 767/4885SLC12A2 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.